Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Peak Bio ( (PKBO) ) just unveiled an announcement.
Peak Bio Inc. has completed a strategic merger with Akari Therapeutics, transforming Peak Bio into a wholly-owned subsidiary of Akari. This merger, effective November 14, 2024, involved converting Peak shares into Akari American Depositary Shares (ADSs) at a 0.2935 exchange ratio, while Peak’s warrants and options were adjusted accordingly. In a concurrent private placement, Akari raised $3.2 million by issuing additional ADSs and warrants. The merger led to significant changes in Peak’s board and executive team, with new leadership taking charge.
See more data about PKBO stock on TipRanks’ Stock Analysis page.